380 related articles for article (PubMed ID: 24909312)
1. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
[TBL] [Abstract][Full Text] [Related]
2. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
Goffin J; Baral S; Tu D; Nomikos D; Seymour L
Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
[TBL] [Abstract][Full Text] [Related]
3. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
4. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M; Kizilbash SH; Laramy JK; Gampa G; Parrish KE; Sarkaria JN; Elmquist WF
Pharm Res; 2018 Jul; 35(9):177. PubMed ID: 30003344
[TBL] [Abstract][Full Text] [Related]
5. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases.
Minniti G; Esposito V; Clarke E; Scaringi C; Lanzetta G; Salvati M; Raco A; Bozzao A; Maurizi Enrici R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):623-9. PubMed ID: 23683828
[TBL] [Abstract][Full Text] [Related]
6. Brain metastasis: opportunity for drug development?
Preusser M; Berghoff AS; Schadendorf D; Lin NU; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):786-94. PubMed ID: 23108247
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
[TBL] [Abstract][Full Text] [Related]
8. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.
Schouten LJ; Rutten J; Huveneers HA; Twijnstra A
Cancer; 2002 May; 94(10):2698-705. PubMed ID: 12173339
[TBL] [Abstract][Full Text] [Related]
9. Brain metastases from non-small-cell lung cancer: is there room for improvement?
Franceschi E; Brandes AA
Expert Rev Anticancer Ther; 2012 Apr; 12(4):421-3. PubMed ID: 22500678
[No Abstract] [Full Text] [Related]
10. αv-Integrin isoform expression in primary human tumors and brain metastases.
Vogetseder A; Thies S; Ingold B; Roth P; Weller M; Schraml P; Goodman SL; Moch H
Int J Cancer; 2013 Nov; 133(10):2362-71. PubMed ID: 23661241
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.
Kourie HR; Kanaan H; Awada G; Awada AH
Future Oncol; 2017 May; 13(12):1097-1103. PubMed ID: 28326837
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials.
Oh Y; Stewart DJ
Oncology (Williston Park); 2008 Feb; 22(2):168-78; discussion 178, 183, 188 passim. PubMed ID: 18409662
[TBL] [Abstract][Full Text] [Related]
14. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann S; Dziadziuszko R; Peters S
Cancer Treat Rev; 2014 Jul; 40(6):716-22. PubMed ID: 24759599
[TBL] [Abstract][Full Text] [Related]
15. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
[TBL] [Abstract][Full Text] [Related]
16. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.
Barnholtz-Sloan JS; Sloan AE; Davis FG; Vigneau FD; Lai P; Sawaya RE
J Clin Oncol; 2004 Jul; 22(14):2865-72. PubMed ID: 15254054
[TBL] [Abstract][Full Text] [Related]
17. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain.
Steiger HJ; Vollmer K; Rogers S; Schwyzer L
Neurosurg Rev; 2022 Oct; 45(5):3119-3138. PubMed ID: 35902427
[TBL] [Abstract][Full Text] [Related]
18. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. A prospective study.
Nieder C
Cancer; 1999 Sep; 86(5):900-3. PubMed ID: 10463993
[No Abstract] [Full Text] [Related]
19. Historic evidence and future directions in clinical trial therapy of solid tumors.
Gollob JA; Bonomi P
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):10-8. PubMed ID: 16773840
[TBL] [Abstract][Full Text] [Related]
20. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
